MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the schedule of key data
Notably, the post-market approval data collected on the Subcutaneous Implantable Defibrillator (S-ICD) System in the U.S., as well as 'real-world' data regarding the efficacy of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, will be presented during late-breaking clinical trial sessions on May 11 and May 12, respectively. Other scheduled presentations and abstracts underscore the following:
"We are pleased to present growing evidence that reinforces the safety and efficacy of technologies across our cardiovascular portfolio," said Kenneth Stein, M.D., senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. "Further, we look forward to results gathered by independent research within the clinical community that embrace our cardiac mapping technology and evaluate the performance of its differentiating features."
ABSTRACTS OF INTEREST (listed chronologically)
Thursday, May 11
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Implantable Defibrillator (ICD)
Friday, May 12
WATCHMAN LAAC Device
CRT-D and ICD
All presentations are listed in Central Time and will take place at McCormick Place West Convention Center. For more information, visit Boston Scientific at booth #1346.
The company will also host an investor event and webcast on May 11 from 4:00-5:00 PM CDT to provide a presentation and answer questions from investors about the Boston Scientific rhythm management portfolio. The event will be accessible via live webcast at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
Caution: The leadless pacemaker is a concept device or technology and not available for use or sale.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Trish BackesMedia Relations(651) 582-5887 (office)Trish.Backes@bsci.com
Susie Lisa, CFAInvestor Relations(508) 683-5565 (office)email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2017-300450632.html
SOURCE Boston Scientific Corporation
Subscribe to our Free Newsletters!
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...
Alzheimer's disease is an irreversible age-related brain disorder that destroys the memory ...View All